Abstract
Normal-tissue adverse effects following radiotherapy are common and signifi - cantly affect quality of life. These effects cannot be accounted for by dosimetric, treatment, or demographic factors alone, and evidence suggests that common genetic variants are associated with radiotherapy adverse effects. The field of radiogenomics has evolved to identify such genetic risk factors. Radiogenomics has two goals: (i) to develop an assay to predict which patients with cancer are most likely to develop radiation injuries resulting from radiotherapy, and (ii) to obtain information about the molecular pathways responsible for radiation-induced normal-tissue toxicities. This review summarizes the history of the field and current research.
Original language | English |
---|---|
Pages (from-to) | 155-165 |
Number of pages | 11 |
Journal | Cancer Discovery |
Volume | 4 |
Issue number | 2 |
DOIs | |
State | Published - Feb 2014 |